| Outcome Measures: |
Primary: Change in HbA1c, Change from baseline in Glycosylated Haemoglobin after 26 weeks of treatment, Week 0 to Week 26 | Secondary: Change in FPG(fasting plasma glucose), Change from baseline in FPG after 26 weeks and 52 weeks of treatment, Week 0 to Week 26, Week 0 to Week 52|Proportion of Subjects with HbA1c<7% and HbA1c≤6.5%, Proportion of subjects with HbA1c\<7% and HbA1c≤6.5% after 26 weeks and 52 weeks of treatment, Week 0 to Week 26 、Week 0 to Week 52|Proportion of Subjects achieving HbA1c targets (HbA1c<7%; HbA1c≤6.5%) and without grade 2 or 3 hypoglycaemia in the last 12 weeks of the treatment period, Week 0 to Week 26, Week 0 to Week 52|Change in HbA1c, Week 0 to Week 52|per-breakfast SMPG, Week 0 to Week 26 、Week 0 to Week 52|8-point SMPG profiles, Week 0 to Week 26 、Week 0 to Week 52|Average daily Insulin dose, Week 0 to Week 26 、Week 0 to Week 52|Proportion of Subjects requiring rescue therapy during treatment, Week 0 to Week 26 、Week 0 to Week 52|Frequency and severity of adverse events, Week 0 to Week 52 + 14 days follow-up|Incidence and rate of Hypoglycemic events, Week 0 to Week 52 + 14 days follow-up|Change in weight, Week 0 to Week 26、Week 0 to Week 52|Anti-drug Antibodies, Week 0 to Week 52 + 14 days follow-up|Serum INS068 concentration, Week 0 to Week 52|Change in scores of diabetes treatment satisfaction questionnaire status version (DTSQs), Week 0 to Week 26 、Week 0 to Week 52
|
